By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

NOXXON Pharma AG 

Max-Dohrn-Strasse 8-10

Berlin    10589  Germany
Phone: 49-30-726247-0 Fax: 49-30-726247-225


SEARCH JOBS


Industry
Pharmaceutical

Segment
Drug Discovery





Company News
NOXXON Pharma AG Presents Updates On Phase II Studies With Olaptesed Pegol (NOX-A12) In CLL And MM And Lexaptepid Pegol (NOX H94) In Anemic Cancer Patients 6/13/2014 9:55:04 AM
NOXXON Pharma AG’s Emapticap Pegol Study Selected For Late Breaking Clinical Trials Symposium During ERA-EDTA Conference 6/2/2014 10:45:37 AM
NOXXON Pharma AG Release: Anti-Hepcidin Spiegelmer® Lexaptepid Pegol Increases Hemoglobin In Subset Of Anemic Patients In Pilot Phase 2a Study 4/8/2014 9:30:45 AM
NOXXON Pharma AG Presents Positive Results From Emapticap Pegol Phase 2a Diabetic Nephropathy Study 4/4/2014 7:14:02 AM
NOXXON Pharma AG Release: Interim Phase IIa Results For Spiegelmer Olaptesed Pegol (NOX-A12) In CLL And MM Studies 12/9/2013 10:25:13 AM
NOXXON Pharma AG Release: Interim Phase 2a Results For Spiegelmer® Olaptesed Pegol (NOX-A12) In CLL And MM Studies 12/9/2013 9:57:27 AM
NOXXON Pharma AG Completes Patient Recruitment for Phase 2 Study in Diabetic Nephropathy 7/24/2013 9:49:18 AM
Two Posters and Two Oral Presentations on NOXXON Pharma AG Compounds at 2012 American Society of Hematology Conference 12/6/2012 10:57:53 AM
NOXXON Pharma AG Initiates Phase IIa of Anti-Hepcidin Spiegelmer® NOX-H94 12/4/2012 10:45:45 AM
NOXXON Pharma AG Initiates Phase IIa Trial of anti-CXCL12/SDF-1 Spiegelmer® 9/26/2012 9:29:10 AM
1234
//-->